Chemical compounds

Karyopharm Announces Investor and Analyst Event at the American Society of Hematology 2020 Annual Meeting

Tuesday, December 1, 2020 - 9:05pm

NEWTON, Mass., Dec. 1, 2020 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will host a virtual investor and analyst event to discuss the Company's pipeline of clinical programs and highlights from the data presentations being given at the American Society of Hematology (ASH) 2020 Annual Meeting.

Key Points: 
  • NEWTON, Mass., Dec. 1, 2020 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will host a virtual investor and analyst event to discuss the Company's pipeline of clinical programs and highlights from the data presentations being given at the American Society of Hematology (ASH) 2020 Annual Meeting.
  • This Karyopharm-sponsored event is scheduled for Tuesday, December 8, 2020 from 1:00 - 2:30 p.m.
  • A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations .
  • In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma.

Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020

Tuesday, December 1, 2020 - 3:01pm

The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020.

Key Points: 
  • The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020.
  • The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients.
  • RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication.
  • We are pleased to advance RP7214 into a Phase 1 clinical trial for the treatment of Covid-19 under a US FDA IND.

Karyopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tuesday, December 1, 2020 - 12:00pm

We look forward to their contributions as we enter this next chapter of growth for XPOVIO(selinexor) and our emerging clinical pipeline."

Key Points: 
  • We look forward to their contributions as we enter this next chapter of growth for XPOVIO(selinexor) and our emerging clinical pipeline."
  • Dr. Mitchener added, "I am delighted to join the Karyopharm team to help expand the global potential of XPOVIO and Karyopharm's growing pipeline.
  • The stock option was granted as an inducement material to Dr. Mitchener entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE®) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC)

Monday, November 30, 2020 - 9:58pm

ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas.

Key Points: 
  • ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas.
  • Programs with Fast Track designation may benefit from early and frequent interactions with the FDA over the course of drug development.
  • PharmaEngine is a commercial stage oncology company headquartered in Taipei and is responsible for the commercialization of ONIVYDE in Taiwan.
  • Limitation of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas.

Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Monday, November 30, 2020 - 2:15pm

The NDA submission includes data from the SURE-1, SURE-2 and SURE-3 phase 3 clinical trials, in which oral sulopenem was well tolerated with no significant drug related adverse events.

Key Points: 
  • The NDA submission includes data from the SURE-1, SURE-2 and SURE-3 phase 3 clinical trials, in which oral sulopenem was well tolerated with no significant drug related adverse events.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.
  • Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
  • Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Global Prostate Cancer Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com

Monday, November 30, 2020 - 12:02pm

3.1 Global Prostate Cancer Market: An Analysis

Key Points: 
  • 3.1 Global Prostate Cancer Market: An Analysis
    3.1.2 Global Prostate Cancer Drug Market by Country (US, China, ROW)
    3.1.3 Global Prostate Cancer Market by Drugs (Enzalutamide, Abiraterone acetate, Leuprorelin, Goserelin, Cabazitaxel, Bicalutamide, Radium 223 dichloride, others)
    3.2 Global Prostate Cancer Market: Drug Analysis
    4.1 The US Prostate Cancer Market: An Analysis
    4.2 The US Prostate Cancer Market: Drug Analysis
    4.3 China Prostate Cancer Market: An Analysis
    4.4 China Prostate Cancer Market: Drug Analysis
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005511/en/

Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor

Monday, November 30, 2020 - 12:00pm

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK in patients with second-line gastrointestinal stromal tumor (GIST).

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK in patients with second-line gastrointestinal stromal tumor (GIST).
  • The INTRIGUE Phase 3 clinical study is a randomized, global, multicenter, open-label study to evaluate the efficacy and safety of QINLOCK compared to sunitinib in patients with GIST previously treated with imatinib.
  • This study was designed to support regulatory approvals in second-line GIST patients in the United States, Europe, and other major markets.
  • QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera, Deciphera Pharmaceuticals, and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.

CTI BioPharma Announces Publication of Article Highlighting Pacritinib Data from the PAC203 Phase 2 Study in Myelofibrosis in Blood Advances

Monday, November 30, 2020 - 12:00pm

SEATTLE, Nov. 30, 2020 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances.

Key Points: 
  • SEATTLE, Nov. 30, 2020 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances.
  • The article, titled "Determining the Recommended Dose of Pacritinib: Results from the PAC203 Phase 2 Dose-Finding Study in Patients with Advanced Myelofibrosis" is available online via this link .
  • PAC203 Phase 2 was an open-label, randomized, dose-finding trial of pacritinib in patients with myelofibrosis who were previously treated with ruxolitinib.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

Global Isobutyl Benzene Market Report 2020-2024: Market is Poised to Grow by $11.51 Million - ResearchAndMarkets.com

Monday, November 30, 2020 - 10:56am

The "Global Isobutyl Benzene Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Isobutyl Benzene Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The isobutyl benzene market is poised to grow by $ 11.51 mn during 2020-2024, progressing at a CAGR of 4% during the forecast period.
  • This study identifies the high production of isobutyl benzene in APAC as one of the prime reasons driving the isobutyl benzene market growth during the next few years.
  • The reports on the isobutyl benzene market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Pond Technologies Holdings Inc. Announces Filing of 2020 Third Quarter Unaudited Interim Condensed Financial Statements and MD&A

Friday, November 27, 2020 - 11:16pm

Located in Markham, Ontario, Pond is a technology leader in controlled environment cultivation of micro-algae.

Key Points: 
  • Located in Markham, Ontario, Pond is a technology leader in controlled environment cultivation of micro-algae.
  • In over ten years of R&D, Pond has developed a robust disruptive technology platform based on artificial intelligence, proprietary LED-lights and patented CO2-Management.
  • Pond is currently selling micro-algae derived antioxidant Astaxanthin under its Regenurex brand.
  • SOURCE Pond Technologies Holdings Inc.